Fennec Pharmaceuticals Inc (TSX:FRX)

C$ 8.57 0.13 (1.54%) Market Cap: 235.09 Mil Enterprise Value: 223.53 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 30/100

Q3 2024 Fennec Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2024

C$6.08 (-11.37%)

Earnings
Q2 2024 Fennec Pharmaceuticals Inc Earnings Call Transcript
Aug 13, 2024

C$8.16 (-5.34%)

Earnings
Q4 2023 Fennec Pharmaceuticals Inc Earnings Call Transcript
Mar 21, 2024

C$13.18

Earnings
Fennec Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2023
Q3 2023 Fennec Pharmaceuticals Inc Earnings Call Transcript
Nov 06, 2023

C$10.96 (+17.60%)

Earnings
Q2 2023 Fennec Pharmaceuticals Inc Earnings Call Transcript
Aug 03, 2023

C$10.63 (-5.68%)

Earnings
Fennec Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 12, 2023
Q1 2023 Fennec Pharmaceuticals Inc Earnings Call Transcript
May 11, 2023

C$10.17 (-4.69%)

Earnings
Fennec Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
Fennec Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 14, 2022

Q2 2024 Fennec Pharmaceuticals Inc Earnings Call Transcript

Aug 13, 2024 / 12:30PM GMT

Release Date Price: C$8.16 (-5.34%)

Transcript 10-Q

Operator

Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals second quarter 2024 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.

Now I'd like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade. Please go ahead.

Robert Andrade

Fennec Pharmaceuticals Inc - Chief Financial Officer

Thank you, operator, and good morning, everyone. We appreciate you joining us today for Fennec Pharmaceuticals' second quarter 2024 earnings conference call, during which we will review our financial results as well as provide a general business update.

Joining me from Fennec this morning is our newly appointed Chief Executive Officer and Board member, Jeff Hackman. Jeff joined Fennec on August 5 and brings more than 30 years of commercial leadership, including oversight of more than 10 product launches across a wide range of therapeutic areas and markets. Importantly, Jeff has successfully commercialized products that are specifically relevant to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.